Waiting for PARIS—A Biological Target in Search of a Drug: PARIS farnesylation: Considerations in addressing a new biological target for neuroprotection in patients with Parkinson’s disease

A recent breakthrough paper published in Science Translational Medicine has provided compelling evidence that inhibition of Parkin Interacting Substrate (PARIS) may offer clinical researchers an important new therapeutic approach since it shows considerable promise as an important biological target...

Descripción completa

Detalles Bibliográficos
Autores principales: Wyse, Richard K., Stott, Simon R.W., Mursaleen, Leah, Matthews, Helen, Dawson, Valina L., Dawson, Ted M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842778/
https://www.ncbi.nlm.nih.gov/pubmed/34744054
http://dx.doi.org/10.3233/JPD-212945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842778/
https://www.ncbi.nlm.nih.gov/pubmed/34744054
http://dx.doi.org/10.3233/JPD-212945

Ejemplares similares